Zynerba Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary

Zynerba Pharmaceuticals

15/08/2023 02:12

* Zynerba Pharmaceuticals Inc  ZYNE.OQ  reported a quarterly
adjusted loss of 21 cents​​ per share for the quarter ended in
June. The mean expectation of three analysts for the quarter was
for a loss of 20 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Zynerba Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 21 cents​.
    * The mean earnings estimate of analysts had fallen by
about 0.9%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Zynerba Pharmaceuticals Inc shares had risen by 4.0% this
quarter and lost 36.0% so far this year.
    * The company reported a quarterly loss of $10.78 million.
    * Wall Street's median 12-month price target for Zynerba
Pharmaceuticals Inc is $5.20 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 15 at 01:12 a.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.20          -0.21          Missed
 Mar. 31 2023      -0.19          -0.21          Missed
 Dec. 31 2022      -0.18          -0.18          Met
 Sep. 30 2022      -0.22          -0.20          Beat